Skip to main content
SRPT
NASDAQ Life Sciences

Sarepta Q3 2026: ELEVIDYS Revenue Falls 37% to $83.5M, Net Loss Narrows to $28.5M

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$17.57
Mkt Cap
$1.856B
52W Low
$14.68
52W High
$24.68
52W Position info
20% above low
Off High info
29% below high
Rel. Volume info
0.7× avg
Market data snapshot near publication time

SRPT sits 20% above its 52-week low of $14.68.

Summary

Sarepta's Q3 2026 revenue fell 5% to $381.4 million as ELEVIDYS US sales dropped 37% to $83.5 million, producing a $28.5 million net loss; the nine-month $297.6 million profit rests on one-time Roche collaboration revenue.


Key Events · Earnings and Guidance · SRPT

  • ELEVIDYS Sales Collapse Continues

    US ELEVIDYS net product revenue fell 37% to $83.5 million in Q3 2026 from $131.5 million a year earlier; nine-month revenue dropped 64% to $283.5 million from $788.3 million, reflecting the 2025 safety events and the November 2025 label removal of non-ambulatory patients.

  • Quarter Swings to Net Loss

    Q3 2026 net loss was $28.5 million (-$0.27 per share) versus a $50.6 million loss a year ago, as total revenue fell 5% to $381.4 million while cost of sales rose 25% to $188.5 million.

  • $62M Catalent Take-or-Pay Charge

    Sarepta elected not to manufacture certain Catalent inventories and recorded a $62.0 million take-or-pay charge in cost of sales; $22.1 million remained unpaid in accrued expenses at September 30, 2026, and an October 2026 letter amendment resolved the underlying obligation.

  • Nine-Month Profit Is One-Time Driven

    The $297.6 million nine-month net income includes $325.0 million of collaboration revenue from Roche declining an option and a $40.0 million Japan dosing milestone, plus a $39.0 million litigation settlement charge for the REGENXBIO/UPenn/Catalent deal.


Analysis · SRPT · Life Sciences

The commercial damage from the 2025 ELEVIDYS safety events and label restriction is now clear: US ELEVIDYS sales dropped 37% year over year to $83.5 million, and nine-month ELEVIDYS revenue is down 64% to $283.5 million. Total revenue slipped 5% to $381.4 million while cost of sales rose 25% to $188.5 million, driven by a $62.0 million Catalent take-or-pay charge, so the quarter flipped to a $28.5 million net loss from a $50.6 million loss a year ago. The nine-month profit of $297.6 million is largely one-time collaboration revenue — $325.0 million from Roche declining an option plus a $40.0 million Japan milestone — not recurring product sales. Cash and investments of $998.7 million plus an undrawn $600.0 million revolver are stated to fund operations for at least twelve months, but the company still faces a $158.6 million 2027 notes maturity and a February 28, 2027 PDUFA date on the VYONDYS 53/AMONDYS 45 supplements after the ESSENCE trial missed its primary endpoint.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, SRPT was trading at $17.57 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.9B. The 52-week trading range was $14.68 to $24.68. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

SRPT - Latest Insights

SRPT
Nov 05, 2026, 4:10 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $17.93
Real-time Price: $13.60 info
Change: -$4.33 (-24%) info
Market Cap: $1.429B info
SRPT
Nov 05, 2026, 4:05 PM EST
Source: BusinessWire
Importance Score:
8
Price at Filing: $16.65
Real-time Price: $13.60 info
Change: -$3.05 (-18%) info
Market Cap: $1.429B info
SRPT
Sep 30, 2026, 8:30 AM EDT
Source: BusinessWire
Importance Score:
7
Price at Filing: $18.64
Real-time Price: $13.60 info
Change: -$5.04 (-27%) info
Market Cap: $1.429B info
SRPT
Sep 23, 2026, 4:18 PM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $19.03
Real-time Price: $13.60 info
Change: -$5.43 (-29%) info
Market Cap: $1.429B info
SRPT
Jul 27, 2026, 9:08 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $16.35
Real-time Price: $13.60 info
Change: -$2.75 (-17%) info
Market Cap: $1.429B info